versicolor exhibited strong affinity for key oncogenic targets such as CDK2, Bcl-2, and VEGFR-2 ( Immunomodulatory effects further contribute to their therapeutic potential: C
Patients experiencing persistent palpitations, chest pain, or irregular heartbeat should contact their GP for cardiovascular assessment
Ascorbic acid may increase the risk of iron toxicity in patients with hemochromatosis, therefore, patients with hemochromatosis should limit their intake of ascorbic acid to no more than 500 mg/day
Druckers current CIHR grant is funding his team to look at how glucagon-like peptides, such as GLP-1, control heart disease and liver disease
Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss
For more information, please visit or contact the VA Information Resource Center (VIReC) at [email protected]